Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon gamma + MELITAC 12.1
- Development stage
- Unknown
- Lead developer
- University of Virginia
- Modality
- Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intratumoral, Subcutaneous, Intradermal
01
Overview
This is an investigational combination immunotherapy consisting of recombinant interferon gamma (IFN-gamma) and the MELITAC 12.1 peptide vaccine, developed by Craig L. Slingluff Jr. at the University of Virginia. The therapy is designed for patients with melanoma, specifically those with cutaneous or subcutaneous metastases. Interferon gamma is administered intratumorally to activate the immune microenvironment and induce chemokines like CXCL9, CXCL10, and CXCL11, which facilitate T-cell recruitment. The MELITAC 12.1 component is a multipeptide vaccine containing 12 class I MHC-restricted melanoma peptides and a tetanus helper peptide, emulsified in Montanide ISA-51 adjuvant, intended to stimulate a systemic anti-tumor T-cell response.
- Other names
- intratumoral interferon gamma plus MELITAC 12.1IFN-gamma + MELITAC 12.1 vaccine
02
Targets
IFNGR1 (Interferon gamma receptor 1)MART-1/HLA-A*02:01 (Melanoma-associated antigen (Melanoma antigen recognized by T cells 1, Melanocyte protein PMEL, Tyrosinase) peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on interferon gamma + MELITAC 12.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon gamma + MELITAC 12.1.